BLIS Technologies Limited (NZE:BLT)

Market Cap	20.47M +6.7%
Revenue (ttm)	14.71M +16.2%
Net Income	692.00K -17.4%
EPS	0.00 -23.7%
Shares Out	1.28B
PE Ratio	32.00
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,393
Open	0.0160
Previous Close	0.0160
Day's Range	0.0160 - 0.0160
52-Week Range	0.0140 - 0.0220
Beta	0.64
Analysts	n/a
Price Target	n/a
Earnings Date	May 22, 2026

About BLIS Technologies

BLIS Technologies Limited, together with its subsidiaries, develops and sells healthcare products based on strains of bacteria that produce bacteriocin activity in New Zealand, Asia Pacific, Europe Middle East and Africa, and North America. The company offers BLIS K12, an oral probiotic supplement to support ear, nose, and throat health, as well as for enhancing immunity and bad breath; BLIS M18, an oral probiotic to support teeth and gums health; and BLIS Q24, a probiotic supplement to balance the skin microbiome, restoring the health, clarity...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 38
• Stock Exchange: New Zealand Stock Exchange
• Ticker Symbol: BLT

Financial Performance

In fiscal year 2026, BLIS Technologies's revenue was 14.71 million, an increase of 16.16% compared to the previous year's 12.67 million. Earnings were 692,000, a decrease of -17.42%.